巴西和印度计划在卢拉访问期间联合生产毒品以降低成本、加强健康保障。 Brazil and India plan joint drug production to cut costs and boost health security during Lula’s visit.

在卢拉总统访问期间,巴西正努力从进口印度药品转向在当地共同生产非专利药品和活性药物原料,卫生部长亚历山大·帕迪拉领导了关于合资企业、技术转让和监管协调的谈判。 Brazil is pursuing a shift from importing Indian medicines to co-producing generics and active pharmaceutical ingredients locally, during President Lula’s visit, with Health Minister Alexandre Padilha leading talks on joint ventures, technology transfer, and regulatory alignment. 新组建的巴西印度制药业协会旨在促进投资和伙伴关系。 The newly formed Brazilian Association of the Indian Pharmaceutical Industry aims to boost investments and partnerships. 官员说当地制造业可以加强健康保障,降低药物成本,创造高价值的工作。 Officials say local manufacturing could enhance health security, cut drug costs, and create high-value jobs. 印度是全球最大的廉价非专利药品供应商,表示有兴趣扩大业务范围。 India, a top global supplier of affordable generics, expressed interest in expanding operations. 合作还包括更快的药物批准和AI驱动的数字健康创新。 Collaboration also includes faster drug approvals and AI-driven digital health innovations. 这项努力是两个金砖国家之间更广泛的战略伙伴关系的一部分。 The effort is part of a broader strategic partnership between two BRICS nations.